Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo D5W Clear all

Conditions: Persistent Pulmonary Hypertension, Respiratory Failure
Interventions: Intravenous Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: Alcoholic Hepatitis, Sepsis
Interventions: Vitamin C, Dextrose 5% in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Neuropathic Pain
Interventions: Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Transposition of Great Vessels, Congenital Heart Disease
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 3 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chemotherapy-induced Neutropenia
Interventions: Plinabulin, Pegfilgrastim, Saline Placebo, D5W Placebo; Drug · Other
Lead sponsor: BeyondSpring Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Stanford, California • Skokie, Illinois • Louisville, Kentucky

Conditions: Pancreatectomy
Interventions: Lidocaine, Placebo D5W; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Migraine, Headache
Interventions: Magnesium Sulfate, Metoclopramide 10mg, Prochlorperazine (Compazine) Injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Heart Failure, Diabetes
Interventions: Thiamine, Placebo; Drug
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Springfield, Massachusetts

Conditions: Hysterectomy
Interventions: IV N-acetylcysteine, IV Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Post-Treatment Lyme Disease Syndrome
Interventions: Ceftriaxone treatment, Placebo; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions: TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W); Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions: CMV hyperimmune globulin, Placebo; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Delafloxacin, Vancomycin, Aztreonam, Placebo; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more

Conditions: Acute Liver Failure, Hepatic Encephalopathy
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: Up to 18 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post-Treatment Lyme Disease
Interventions: Ceftriaxone (Rocephin®), Dextrose 5% (D5W); Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
Interventions: Trilaciclib, Placebo, Docetaxel; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more

Conditions: Skin Diseases, Bacterial
Interventions: Oritavancin, Placebo (D5W); Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Somers Point, New Jersey

Conditions: BK Virus Infection
Interventions: MAU868, Placebo; Drug · Other
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more

Conditions: Insulin Sensitivity
Interventions: Eritoran, D5W; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ureaplasma Infections
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 2 Hours to 72 Hours
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more

Conditions: Postoperative Ileus
Interventions: 5% dextrose in water, TZP-101; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more

Conditions: Ambulatory IPF
Interventions: Rituximab, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Hernia, Paraesophageal
Interventions: IV lidocaine, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Search by objective public record fields.

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

Thiamine and Acute Decompensated Heart Failure: Pilot Study

NAC vs Placebo on Opioid Use for Hysterectomy

Ceftriaxone for Post-Treatment Lyme Disease

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo